In the past decade, we have observed exciting advances in lung cancer therapy, including the development of targeted therapies. However, additional strategies for early detection and tumor-based therapy are still essential in improving patient outcomes. EGF receptor (EGFR) and MET (the receptor tyrosine kinase for hepatocyte growth factors) are cell-surface tyrosine kinase receptors that have been implicated in diverse cellular processes and as regulators of several microRNAs (miRNAs), thus contributing to tumor progression. Here, we demonstrate a biological link between EGFR, MET, and the miRNA cluster 23a∼27a∼24-2. We show that miR27a regulates MET, EGFR, and Sprouty2 in lung cancer. In addition, we identify both direct and indirect mechanisms by which miR-27a can regulate both MET and EGFR. Thus, we propose a mechanism for MET and EGFR axis regulation that may lead to the development of therapeutics in lung cancer.
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cell signaling | epigenetics L ung cancer remains the number one cause of cancer-related deaths among men and women. However, in the past several years, we have witnessed some major advances in therapeutics that have improved outcomes in selected subgroups of patients. Tyrosine kinase receptors continue to be investigated as therapeutic targets in lung cancer. The receptor tyrosine kinase for hepatocyte growth factors, MET, is a membrane receptor for the hepatocyte growth factor (HGF) (1); MET tyrosine kinase is known to promote survival of many cell types following exposure to various apoptotic inducers, including serum starvation, death receptor activation, or genotoxic treatment (2). MET protein expression and phosphorylation have been associated with primary resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in non-small cell lung cancer (NSCLC) patients (3) . EGFR is a membrane receptor overexpressed in most NSCLC tumors, and its activation and signaling contribute to both the growth and maintenance of epithelial tissues (4) (5) (6) . MET and EGFR are normally expressed by cells of epithelial origin and, upon ligand stimulation, induce cancer cell invasion, thus increasing metastatic potential. This effect on invasion occurs primarily through increased phosphorylation of both ERK1/2 and the ETS domain containing protein (ELK)1 transcriptional factor (7) (8) (9) . MET and EGFR protein levels are positively regulated by Sprouty2 protein expression (10) (11) (12) . Sprouty2 is ubiquitously expressed at different levels in human tissues (13) . Sprouty2 expression has been shown to increase MET protein levels in colon adenocarcinoma and also to increase EGFR levels by attenuating EGFR degradation by ubiquitination (10, 12, 14) . MicroRNAs (miRNAs) are small noncoding RNAs of 19-25 nt that can inhibit mRNA translation and/or negatively regulate mRNA stability (15) . MiRNA dysregulation is one of the most important factors contributing to cancer development (16) and has been implicated in cancer drug resistance (17) . Several miRNAs are indeed involved in cancer initiation and progression such as miR-15 and miR-16, targeting B-cell lymphoma 2 (Bcl-2) in leukemias (18) . In addition, miRNAs such as miR-494 targeting Bcl-2-like protein 11 (BIM) (19) and miR-130a targeting MET (20) can alter drug resistance. Investigators have reported that MET can regulate miRNA expression (17, 21) . It is also known that Sprouty2 is a validated target of miR-27a in pancreatic cells (22) . MiR-27a belongs to the miR-23a∼27a∼24-2 cluster that promotes cell proliferation in several cancers (23, 24) but can also function as a potent inducer of apoptosis in 293 cell lines (25) . MiR-27a is down-regulated in serum and plasma of NSCLC patients (26) and inhibits the proliferation of gastric cancer cells (27) . However, the biological relationships between Sprouty2, MET, and EGFR protein levels in NSCLC have not previously been investigated. In the current study, we sought to determine if such relationships exist in NSCLC. Herein, we demonstrated that MET regulates the miR-23a∼27a∼24-2 cluster, which, in turn, down-regulates MET and EGFR protein levels in NSCLC cells. Furthermore, we identified a mechanism that links miR-27a, MET and EGFR that also involves Sprouty2, thus illustrating cross-talking between MET and EGFR in NSCLC.
Results
MET Regulates miR-23∼27a∼24-2 Cluster Expression in NSCLC. Hepatocyte growth factor (HGF) binds its receptor MET and regulates cell growth, motility, and morphogenesis by activating the MET tyrosine kinase signaling cascade (9, 28) . MET is basally activated in A549 cells (29) (30) (31) and is also a potent transcriptional regulator of miRNA expression. It has been previously reported that the miR-221 and miR-222 cluster, and miR-30b/c, miR-103, and miR-203 are all regulated by MET in NSCLC (17, 21) . To further investigate the role of MET in miRNA regulation, we stably silenced MET in A549 lung cancer cells using lentiviral particles (Fig. 1A) and conducted a high-throughput array for miRNA expression. Among MET knockdown (MET-KD) cells, we identified that miR-23a, miR-27a, and miR-24-2 were all significantly (P < 0.05) down-regulated (Fig. 1B) . It has been previously reported that these miRNAs exist as a cluster and share the same promoter, thus harboring similar regulatory patterns (Fig. 1C) (32, 33) . We validated the expression of this primary (pri)-miRNAs cluster in MET-KD A549 cells using quantitative (q)RT-PCR (Fig. 1D ) and miR-27a by Northern blot and qRT-PCR ( Fig. 1E and Fig. S1B ). We also validated (pri)-miR-23a∼27a∼24-2 cluster down-regulation in an independent cell line (human Caucasian lung epidermoid carcinoma; CALU-1 cells) following lentiviral particle silencing of 23a∼27a∼24-2 cluster expression. As shown in Fig. 1F , the (pri)-miRNA cluster and miR-27a (Fig. S1D ) expressions were increased within 30 min of HGF treatment. Similar results were evident in CALU1 cells ( Fig. S1 C and E). It has been reported in the literature that MET and EGFR signaling have similar roles in the promotion of cellular proliferation, motility, invasion, angiogenesis, and survival (34) (35) (36) . In addition, MET and EGFR regulate similar miRNAs (17) . As with MET, EGFR is also basally active in A549 cells (37) ; for this reason, we hypothesized that EGFR may also regulate miR-23a∼27a∼24-2 expression. Following the silencing of EGFR, however, we did not demonstrate any significant change in the miR-23a∼27a∼24-2 cluster expression in EGFR knockdown compared with the control cells (Fig. S1F) .
MET Regulates miR-27a-23a-24 Cluster Transcription Through ELK1.
We next focused our attention on the transcriptional regulation of the miR-23a∼27a∼24-2 cluster by MET. The human miR23a∼27a∼24-2 cluster promoter has been well described by other investigators (32, 33) . By using the TESS database (http://www.cbil. upenn.edu/cgi-bin/tess/tess), we identified five different ELK1 binding regions in the promoter region for this miRNA cluster ( Fig. 2A) . Previous investigation has shown that MET, by activating the ERK pathway, induces ELK1 transcription factor activation by phosphorylation (7-9). As shown in Fig. 2B , we validated this relationship in A549 cells. To determine whether ELK1 was involved in MET-mediated regulation of the miR-23a∼27a∼24-2 cluster, we first cloned a region of ∼600 bp including the ELK1 binding sites upstream of the luciferase gene into a promoter-less vector luciferase reporter plasmid (pGL3)-basic. The luciferase assay showed that silencing MET or ELK1 in A549 and H1299 cells decreased the miRNA cluster promoter luciferase activity compared with the control cells ( Fig. 2C and Fig. S2A ). To verify a direct binding of ELK1 on the miR-23a∼27a∼24-2 cluster promoter, we performed a chromatin immunoprecipitation (ChIP) assay. The chromatin region of the miRNA cluster promoter to be analyzed was ∼400 bp in length and included all five ELK1 binding sites. The ChIP assay showed a direct link between ELK1 and the miR-23a∼27a∼24-2 cluster promoter that became weaker when MET was silenced (Fig. 2D) . To further validate ELK1 in the regulation of the miR-23a∼27a∼24-2 cluster, we silenced ELK1 in A549 cells. As shown in Fig. 2E , ELK1 knockdown decreased (pri)-miRNA cluster expression in A549 cells compared with the scrambled control. We also silenced ELK1 in MET-KD A549 cells and evaluated the (pri)-miR-23a∼27a∼24-2 cluster expression levels by qRT-PCR (Fig. S2B) . The effect of MET knockdown on miR-23a∼27a∼24-2 cluster expression levels was less robust when ELK1 was silenced compared with the scrambled control, suggesting that ELK1 is one of the transcriptional factors involved in this process.
MiR-27a, a Member of miR-23a∼27a∼24-2 Cluster, Targets MET and EGFR in NSCLC. We performed a bioinformatic search (Targetscan, RNAhybrid, Pictar) to identify putative mRNA 3′ UTR targets for the mature miRNAs belonging to miR-23a∼27a∼24-2 cluster. Among them, we found that miR-27a had a seed region that matched the 3′ UTR of human MET (nucleotide 1564-1571; NM_000245) (Fig. 3A, Left) . To verify that MET was a direct target of miR-27a, the MET 3′ UTR containing the miR-27a binding site was cloned into the pGL3 control vector downstream of the luciferase ORF. This reporter construct was used to transfect 293 cells. Cotransfection of miR-27a with the WT MET 3′-UTR construct in 293 cells resulted in a significant inhibition of luciferase activity compared with the negative control (Fig. 3B, Left) . Mutagenesis of the miR-27a binding site within the MET 3′ UTR abolished the ability of miR-27a to regulate the luciferase expression (Fig. 3 A, Left and B, Right) . In addition, overexpression of miR-27a in A549 cells strongly reduced the endogenous protein and mRNA levels of MET compared with the control (Fig. 3 D and E) . Increased expression of miR-27a in A549 transfected cells was confirmed by qRT-PCR (Fig. 3G ). MiR27a was able to reduce the endogenous expression of MET also in CALU-1 and H1299 lung cancer cell lines (Fig. S3 A, B, E,  and F) . MiR-27a is also predicted to target the 3′ UTR of human EGFR (nucleotide 200-207 and nucleotide 430-436 NM_005228). MiR-27a has two seed regions that match the 3′ UTR of human EGFR and for this reason it is a robust candidate for miRNA targeting (Fig. 3A , Center and Right). To verify that EGFR is a direct target of miR-27a, we cloned the EGFR 3′ UTR containing the miR-27a binding sites into the pGL3 control vector downstream the luciferase ORF. This reporter construct was used to transfect 293 cells. Cotransfection of miR27a and the WT EGFR 3′-UTR construct in A549 cells resulted in significant inhibition of luciferase activity compared with the negative control (Fig. 3C, Left) . Mutation of the miR-27a binding sites within the EGFR 3′ UTR abolished the ability of miR-27a to regulate the luciferase expression (Fig. 3 A, Center and Right and C, Right). In addition, miR-27a overexpression reduced both the endogenous protein and mRNA levels of EGFR in A549 cells compared with the control (Fig. 3 D and F) . The increased expression of miR-27a in transfected cells was confirmed by qRT-PCR (Fig. 3G) . MiR-27a also reduced the endogenous expression of EGFR in CALU-1 and H1299 NSCLC cell lines (Fig. S3 A, C , E, and G). MiR-27a ectopic expression was validated by qRT-PCR (Fig. S3 D and H) .
MiR-27a Reduces MET and EGFR Levels in NSCLC Through Targeting
Sprouty2. MiR-27a directly targets Sprouty2 in tumoral pancreatic cells (22) . To confirm a similar function for Sprouty2 in NSCLC cells lines, we transfected miR-27a in A549, H1299, and CALU-1 cell lines. The ectopic expression of miR-27a resulted in a reduction in Sprouty2 mRNA and endogenous protein levels in all three NSCLC cell lines (Fig. 4 A-C) . Sprouty2 is also able to modulate EGFR protein levels by attenuating EGFR degradation by ubiquitination (10) . MET is also regulated by Sprouty2 in colon carcinoma by a not yet determined mechanism (12) . A549, H1299, and CALU1 cells were transfected with a scrambled siRNA or with Sprouty2 siRNA followed by immunoblot for MET and EGFR protein levels. Sprouty2 silencing resulted in a reduction in both MET and EGFR levels compared with a scrambled control (Fig. 4 D-F) . We decided to verify whether miR-27a, which down-regulates MET and EGFR protein levels by direct targeting, was also able to modulate their endogenous levels by targeting Sprouty2. MiR-27a was stably overexpressed in A549 cells (Fig. 5A ) and Sprouty2 was silenced by siRNA. As shown in Fig. 5B , Sprouty2 silencing led to an increase miR-27a mediated down-regulation of MET and EGFR protein levels. These findings suggest that Sprouty2 down-regulation augments the effects of miR-27a on MET and EGFR expression. Conversely, the ability of Sprouty2 silencing to cause MET and EGFR down-regulation was weaker when miR-27a was not overexpressed. The proposed schema by which cross-talk occurs between MET, EGFR, miR-27a, and Sprouty2 is represented in Fig. 5C .
Discussion
A correlation between MET and EGFR expression and drug resistance in cancer has been extensively described in the literature (17, 38, 39) and both MET and EGFR represent viable therapeutic targets in cancer. In addition, investigators have demonstrated that MET and EGFR can serve as transcriptional regulators of miRNAs (17) . However, the regulatory pathways between MET, EGFR, and miRNA have not been fully clarified in NSCLC. In the current study, we provide evidence that the MET receptor tyrosine kinase regulates the miR-23a∼27a∼24-2 cluster expression through ELK1. Here, we also validate EGFR and MET as targets of miR-27a in NSCLC. Altered expression for the miR-23a∼27a∼24-2 cluster has been described in many tumors (33) . This cluster has been shown to give rise to contrasting phenotypes in different cell types (25, 40) . Herein, we validated MET as a regulator of miR-23a∼27a∼24-2 cluster expression in a process that involves its ligand, HGF. We next sought to identify the mechanisms by which MET induces miR23a∼27a∼24-2 cluster expression. We identified a region within the cluster promoter with five binding sites for the transcription factor ELK1. Our observations were consistent with previous reports that ELK1 is susceptible to upstream transcriptional regulation by activated MET (7) (8) (9) . Therefore, we focused our attention on the likelihood that ELK1 may serve as a mediator of MET regulation of the miR-23a∼27a∼24-2 cluster. We verified that ELK1 is one of the transcription factors responsible for the induction of miR23a∼27a∼24-2 cluster expression. MiR-27a, a member of miR23a∼27a∼24-2 cluster, was predicted to target both MET and EGFR 3′ UTRs. MiR-27a expression is up-regulated in breast cancer (41) but down-regulated in colorectal cancer and oral squamous carcinoma and expressed at low levels in both the serum and plasma of NSCLC patients (26, 42, 43) . It is also reported that an reference single nucleotide polymorphism (rs)895819 SNP was found in precursor miRNA (premiR)-27a in NSCLC patients (44) . As shown in Figs. 3 and 4 , miR-27a directly targets MET and EGFR 3′ UTRs, down-regulating their expression in NSCLC cell lines. It is reported that miR-27a also directly targets Sprouty2 protein in colon cancer (22) . Because MET and EGFR protein levels are positively regulated by Sprouty2, we sought to validate this potential relationship. Interestingly, Sprouty2 silencing resulted in the down-regulation of MET and EGFR protein levels (10) (11) (12) 45) . This is of particular importance given that the effects of Sprouty2 expression on MET and EGFR endogenous levels in NSCLC have not previously been reported. Here, we show that miR-27a is able to target and downregulate Sprouty2 protein levels in NSCLC. We demonstrate that Sprouty2 silencing results in a reduction in both MET and EGFR in NSCLC. Thus, we hypothesized that miR-27a mediated downregulation of MET and EGFR occurred through two different mechanisms: (i) by directly targeting MET and EGFR mRNA 3′ UTRs and (ii) through Sprouty2 down-regulation. To confirm this hypothesis, we examined the effects of miR-27a overexpression on MET and EGFR protein levels in the setting of Sprouty2 silencing. We showed that miR-27a could reduce MET and EGFR protein levels when Sprouty2 was silenced (Fig. 5B) . These results indicate that MET, but not EGFR (Fig. S1F) , induces miR-23a∼27a∼24-2 expression. Furthermore, a member of this cluster, miR-27a, is able to down-regulate MET and EGFR by either targeting directly their 3′ UTRs or indirectly, by targeting Sprouty2. In summary, we have demonstrated a mechanism for MET regulation of EGFR expression in NSCLC. This understanding of unique molecular pathways and mechanisms for MET and EGFR axis regulation may provide additional strategies for lung cancer treatment in the future.
Materials and Methods
Cells were seeded and grown in RPMI (293, 293TN, H460, A549, H1299) or DMEM (Calu-1) with 10% (vol/vol) FBS, L-glutamine, and antibiotics (Invitrogen). All of the transfections were performed by using Lipofectamine 2000 (Invitrogen), as suggested by the manufacturer. All cell lines used were cultured to 80% confluence in p60 plates in serum-free medium without antibiotics and then transfected with 100 nmol of premiR-27a oligonucleotides or negative control for 48 h or 72 h (Ambion).
ACKNOWLEDGMENTS. This study was supported by National Institutes of Health Grant to CA152758 (to C.M.C.). Following infection, MET and EGFR protein levels were assessed by immunoblot (Top) and miR-27a expression by qRT-PCR (Bottom). (B) Sprouty2 was silenced in A549 miR-27a stable cells; a scrambled siRNA was used as control. An immunoblot was performed to assess MET, EGFR, and Sprouty2 endogenous protein levels. Loading control was obtained by using an anti-GAPDH antibody (Top). A qRT-PCR was performed to validate miR-27a levels (Bottom). (C) Summary diagram of our proposed regulatory pathway: HGF binds MET and induces miR-23a∼27a∼24-2 cluster expression through ELK1. A member of this cluster (miR-27a) directly targets MET and EGFR 3′ UTRs in NSCLC. MiR-27a also targets Sprouty2 3′ UTR; Sprouty2 is able to modulate MET and EGFR protein levels in NSCLC. MiR-27a overexpression directly deregulates MET and EGFR but also indirectly acts on their protein levels by targeting Sprouty2. Error bars, ± SD. P < 0.05.
